Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunome (IMNM)
NASDAQ:IMNM
Holding IMNM?
Track your performance easily
IMNM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.65 - $30.96
Previous Close$15.5
Volume1.47M
Average Volume (3M)792.47K
Market Cap
$930.84M
Enterprise Value$655.02M
Total Cash (Recent Filing)$278.30M
Total Debt (Recent Filing)$2.48M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Nov 11, 2024EPS Estimate
-$0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.69
Shares Outstanding60,054,372
10 Day Avg. Volume595,935
30 Day Avg. Volume792,471
Standard Deviation0.43
R-Squared0.04
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)3.66
Price to Sales (P/S)85.76
Price to Cash Flow (P/CF)-9.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue60.74
Enterprise Value/Gross Profit46.73
Enterprise Value/Ebitda-9.04
Forecast
1Y Price Target
$31.33Price Target Upside104.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Immunome News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe delay in the RINGSIDE trial could suggest the drug is performing better than expected.
Management And StrategyValuable know-how in drug development. Management has a strong track record at Seagen, leading Adcetris and Padcev to market and bringing in differentiated assets.
Pipeline And DevelopmentThe pipeline now combines a pivotal stage asset and multiple early-stage programs in areas that are of significant investor interest.
Bears Say
Drug DevelopmentThe ability to replicate Phase 2 efficacy in the larger Phase 3 is critical for valuation tied to the success of AL102.
Financial CommitmentsIMNM is responsible for up to $142 million in clinical development and regulatory milestones, as well as up to $50 million for commercial milestones, which signifies financial commitments that could impact cash flow.
Share DilutionThe price target for IMNM has been lowered to $38 from $40, primarily due to the share dilution.
---
Ownership Overview
5.55% Insiders
19.33% Mutual Funds
43.72% Other Institutional Investors
31.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $6.65 and its highest was $30.96 in the past 12 months.
What is Immunome’s market cap?
Currently, no data Available
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is Nov 11, 2024 which is in 52 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on Aug 12, 2024. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.379 by -$0.221.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -$0.54.
How many shares outstanding does Immunome have?
Immunome has 60,054,370 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.379. Following the earnings report the stock price went up 7.041%.
Which hedge fund is a major shareholder of Immunome?
Among the largest hedge funds holding Immunome’s share is Woodline Partners LP. It holds Immunome’s shares valued at 11M.
---
Immunome Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.33 (104.91% Upside)
$31.33 (104.91% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 961.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $48.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
112.03%
12-Months-Change
Fundamentals
Return on Equity
-199.56%
Trailing 12-Months
Asset Growth
614.89%
Trailing 12-Months
Company Description
Immunome
Immunome Inc is a biopharmaceutical company engaged in the discovery and development of novel antibody-based drugs. The company's proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. It is developing treatments for treating cancer and other infectious diseases.
---
IMNM Stock 12 Month Forecast
Average Price Target
$31.33
▲(104.91% Upside)
Technical Analysis
Best Analysts Covering IMNM
1 Year
1 Year Success Rate
4/6 ratings generated profit
1 Year Average Return
+8.50%
assigned a buy rating last month
Copying David Nierengarten's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +8.50% per trade.
---